 Funds will be used to complete phase 3 clinical development of eneboparatide AZP-3601 for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegaly LYON, France and CAMBRIDGE, Mass., Jan. 06, 2023 GLOBE NEWSWIRE Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the closing of ... The post Amolyt Pharma Announces 138 Million Series C Financing led by Sofinnova Partners and co-led by Intermed... 